Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
SCYNEXIS, Inc. (SCYX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
7High confidence
0.817Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
SCYNEXIS, Inc. Suppliers
Ticker
Name
Confidence
Evidence
POXEL
POXEL
90%
In connection with the Transaction, Poxel also granted to the Company an exclusive, sublicensable, perpetual and irrevocable, worldwide license under certain licensed intellectual property controlled…
recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. Our clinical stage compound, SCY-247, is not affected by the…
Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERG…
SCYNEXIS, Inc. Customers
Ticker
Name
Confidence
Evidence
GSK
GSK plc
90%
Revenue consists of license agreement revenue associated with the GSK license agreement. | Qwen verified: Explicit mention of GSK license agreement revenue indicates GSK is customer receiving licensi…
GSK
GSK plc
90%
Reciprocal relationship from GSK graph: Reciprocal relationship from SCYX graph: Revenue consists of license agreement revenue associated with the GSK license agreement. | Qwen verified: Explicit men…
recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. Our clinical stage compound, SCY-247, is not affected by the…
Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: Reciprocal relationship from MRK grap…
CHIEF-EXECUTIVE-OFFICER-DR-DAVID-ANGULO-CVI-INVE
CHIEF-EXECUTIVE-OFFICER-DR-DAVID-ANGULO-CVI-INVE
62%
026. The Company paid the $ 8.0 million upfront payment to Poxel in April 2026. In addition, the Company is obligated to pay Poxel milestone payments upon the first achievement of certain development…
SCYNEXIS, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SCYX-DEBT
Debt stack $2.1M
90%
Market cache reports total debt of $2.1M.
SCYX-DEBT-12430
Warrants outstanding: 1319807
90%
xbrl warrant detail from xbrl 2025-12-31.
SCYX-DEBT-12431
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
SCYNEXIS, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for SCYNEXIS, Inc..
SCYNEXIS, Inc. Ownership
Holder
Name
Confidence
Evidence
SCYX-OWNER-SQUADRON-CAPITAL-MANAGEMENT-LLC
Squadron Capital Management LLC
90%
13F overlay lists Squadron Capital Management LLC as top holder; 45 tracked holders.
